bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.24 and traded as low as $0.1506. bioAffinity Technologies shares last traded at $0.1650, with a volume of 2,000 shares.
bioAffinity Technologies Price Performance
The stock has a fifty day moving average of $0.31 and a two-hundred day moving average of $0.24.
About bioAffinity Technologies
bioAffinity Technologies is a biotechnology company focused on developing diagnostic tests for the early detection of lung cancer and other diseases. Its work combines cellular analysis and other diagnostic technologies to support earlier identification of disease.
The company’s lead product, CyPath Lung, is a diagnostic test that analyzes sputum samples using flow cytometry to help assess the likelihood of lung cancer. The test is processed through Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Based in San Antonio, Texas, bioAffinity Technologies has focused its commercial and development activities on lung cancer diagnostics.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
